Deals
23andMe Funding Values Genetics Startup at $1.1 Billion
- Fidelity leads latest round with Google Ventures, NEA
- Proceeds will fund new consumer product, drug discovery
Anne Wojcicki, co-founder and chief executive officer of 23andMe, speaks during a keynote session at the South By Southwest (SXSW) Interactive Festival in Austin, Texas.
Photographer: David Paul Morris/BloombergThis article is for subscribers only.
Silicon Valley genetic-testing company 23andMe Inc. raised $115 million in venture-capital financing as it prepares to introduce a new consumer product and expands its drug-discovery arm.
The Series E funding round was led by Fidelity Management & Research Co. and included previous investors Google Ventures and New Enterprise Associates as well as new backers such as Casdin Capital and WuXi Healthcare Ventures, the firm said Wednesday in a statement. The financing implies a valuation of $1.1 billion for 23andMe, according to a person close to the company.